Urolithin A and longevity research intersect at mitophagy — the process by which cells clear damaged mitochondria. Human trials show urolithin A may improve muscle endurance and reduce inflammatory markers in older adults, though its effect on lifespan itself has not been established in humans. This is not an FDA-approved drug. TelosRX reviews longevity supplement programs subject to medical approval by a licensed provider.
Urolithin A (UA) is a metabolite produced when gut bacteria break down ellagitannins — compounds found in pomegranates, walnuts, and certain berries. Most people don't absorb enough dietary ellagitannins to produce meaningful urolithin A. That's why researchers and supplement companies are studying direct supplementation.
The interest in urolithin A for longevity comes down to one biological process: mitophagy — the selective removal of dysfunctional mitochondria. As mitochondria age and accumulate damage, they generate more reactive oxygen species and produce less energy. Clearing them out, and allowing newer, healthier mitochondria to take their place, is thought to be critical to healthy aging. Urolithin A appears to be one of the most potent natural mitophagy inducers identified in research to date.
Study 1: The First Human Trial — Proof of Mitochondrial Gene Activation
The first human study of urolithin A was published in Nature Metabolism (Andreux et al., 2019) and enrolled 60 healthy sedentary older adults. Participants received 500 mg or 1000 mg of urolithin A daily for 28 days, or placebo.
Key findings:
- 500 mg UA significantly increased gene expression related to autophagy and mitochondrial function in skeletal muscle
- Both doses reduced plasma acylcarnitines — metabolic byproducts associated with poor mitochondrial efficiency
- No significant adverse events were reported
This trial established that urolithin A reaches skeletal muscle in humans and produces measurable mitochondrial and autophagy-related gene changes. It didn't test functional outcomes like strength or endurance — that came next.
Study 2: JAMA Network Open RCT — Muscle Endurance in Older Adults
A randomized clinical trial published in JAMA Network Open (Singh et al., 2022) enrolled 66 adults aged 65–90. Participants received 1000 mg urolithin A daily or placebo for four months. This is the most rigorous human trial to date.
Key findings:
- Urolithin A significantly improved muscle endurance — measured by the number of hand and leg muscle contractions before fatigue — compared to placebo
- Plasma acylcarnitines, ceramides, and C-reactive protein (CRP) all declined significantly in the UA group vs. placebo
- No significant difference in maximal ATP production or 6-minute walk distance, though both trended positive
- No serious adverse events in either group
This is the most robust evidence that urolithin A produces functional benefits — not just biomarker changes — in older humans. Muscle endurance is a genuine functional outcome linked to fall risk, independence, and quality of life in aging populations.
Study 3: 2024 Systematic Review — Anti-Inflammatory and Muscle Strength Effects
A systematic review published in Ageing Research Reviews (2024) from the National University of Singapore analyzed all registered human trials of urolithin A at the time. Five studies, 250 healthy participants total, doses ranging from 10–1000 mg/day for 28 days to 4 months.
Summary of findings across trials:
- UA showed dose-dependent anti-inflammatory effects across studies
- Mitochondrial gene expression and autophagy markers improved
- Muscle strength and endurance improved in the trial with highest-quality design
- No consistent effect on physical function, grip strength, gait speed, or VO2 max in shorter trials
- No effect on gut microbiome composition
- No effect on maximal ATP production in the energy-depleted muscle of very old adults
The reviewers concluded: “There is very limited evidence on the effect of UA in human aging. UA showed some improvement in mitochondrial activity and autophagy. It decreased inflammatory markers and increased muscle strength and endurance.” They also noted small sample sizes and short intervention periods as key limitations.
Study 4: Nature Aging 2025 — Immune System and T Cell Rejuvenation
A 2025 study published in Nature Aging examined urolithin A's effect on immune aging — specifically whether mitophagy-driven UA supplementation could expand younger T cell populations. Preclinical research showed UA expanded T memory stem cells (TSCM) and naive T cells via Wnt signaling and TCF1 induction. The human trial in middle-aged adults found UA improved several immune aging markers.
This adds a new dimension to the UA longevity story: it may slow immune senescence (the gradual decline of immune function with age) — a process linked to increased cancer risk, infection susceptibility, and autoimmune conditions. Human data remains early-stage.
What Urolithin A Does NOT Show (Yet)
Honest summaries require the negatives too:
- No human lifespan extension data exists — animal models show lifespan extension in C. elegans and muscle function benefits in aging mice, but these don't translate directly to human longevity
- No effect on maximal ATP production in the most rigorous trial — suggesting mitochondrial energy output was not improved
- No consistent effect on physical function metrics like gait speed or VO2 max
- Effects may depend on baseline mitochondrial status — healthier individuals may see smaller gains
Urolithin A vs. Other Longevity Compounds
| Compound | Primary Mechanism | Human Evidence Level | Common Use |
|---|---|---|---|
| Urolithin A | Mitophagy induction | 3–4 small RCTs; JAMA published | Oral supplement |
| NMN / NR | NAD+ precursor | Several small trials; mixed results | Oral supplement |
| Spermidine | Autophagy induction | Observational + small trials | Food / supplement |
| Rapamycin | mTOR inhibition | Animal strong; human trials early | Prescription, off-label |
| Epitalon | Telomerase activation (preclinical) | Primarily Khavinson lab; limited | Compounded peptide |
Who Might Consider Urolithin A Research Contexts
Urolithin A is increasingly studied in the context of:
- Healthy older adults concerned with muscle function and longevity
- Athletes interested in mitochondrial health and recovery
- Middle-aged adults beginning preventive longevity protocols
Anyone considering UA as part of a structured longevity protocol should discuss it with a licensed provider, particularly when combining it with other supplements or compounds. TelosRX's asynchronous evaluation process allows a provider to review your full health context before any protocol is recommended, subject to medical approval by a licensed provider.
Interested in a provider-guided longevity protocol? View TelosRX's longevity programs and complete the asynchronous intake form for review by a licensed provider.
Frequently Asked Questions
What is urolithin A and where does it come from?
Urolithin A is a compound produced by gut bacteria when they metabolize ellagitannins, found in pomegranates, walnuts, and certain berries. Because most people's gut microbiome doesn't produce it efficiently, researchers study direct oral supplementation as a more reliable delivery method.
What does urolithin A do for mitochondria?
Preclinical research and human studies suggest urolithin A activates mitophagy — the selective clearance of damaged mitochondria. This allows cells to replace old, inefficient mitochondria with newer ones, which may improve cellular energy production and reduce oxidative stress over time.
Is urolithin A safe?
Human trials at doses of 500–1000 mg/day for up to 4 months found no significant adverse events. It was well-tolerated across age groups. Long-term safety data beyond 4 months is not yet established. Always discuss any supplement with a licensed provider before starting.
Does urolithin A extend lifespan in humans?
Not confirmed. Urolithin A prolongs lifespan in C. elegans and improves muscle function in aging mice. Human trials have demonstrated improved muscle endurance and anti-inflammatory effects. Whether this translates to longer human lifespan has not been studied and cannot be claimed.
How much urolithin A should you take?
Human trials have used 500–1000 mg per day. The 1000 mg dose in the JAMA Network Open trial showed the most robust functional outcomes. Appropriate dosing should be determined by a licensed provider based on individual health status. Not FDA-approved.
What's the difference between urolithin A and NMN or NR?
NMN and NR are NAD+ precursors that aim to increase cellular NAD+ levels. Urolithin A works through a different mechanism — mitophagy induction. They target separate aspects of mitochondrial health and are not directly comparable. Some longevity researchers study combinations, but evidence for combined protocols is limited.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.